Ocuphire Pharma. has been granted a patent for methods and compositions using phentolamine mesylate to treat presbyopia and other ocular disorders. The claimed method involves administering a 1% solution as eye drops, resulting in a significant improvement in near-vision visual acuity. GlobalData’s report on Ocuphire Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Ocuphire Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Ocuphire Pharma's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of presbyopia using phentolamine eye drops
A recently granted patent (US12016841B2) outlines a method for treating presbyopia, a common age-related vision condition, using a monotherapy regimen. The method involves administering a single therapeutic agent, phentolamine mesylate, in the form of a 1% (w/w) eye drop solution. The treatment aims to enhance near-vision visual acuity, with claims indicating that patients can experience at least a two-line improvement on a vision chart. The patent also specifies that the therapeutic effect can last for varying durations, with claims supporting effects lasting at least 6, 12, or even 18 hours post-administration.
Additional claims detail the expected outcomes of the treatment, including a potential three-line improvement in visual acuity and minimal side effects, such as an increase in eye redness of no more than one grade on the CCLRU Redness Grading Scale. The method is designed to produce a pupil diameter of less than 3.0 mm under photopic conditions, indicating a specific physiological response to the treatment. Furthermore, the patent claims that therapeutic benefits can be observed within one hour of administering the eye drops, providing a rapid response for patients seeking relief from presbyopia symptoms.
To know more about GlobalData’s detailed insights on Ocuphire Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
